{
  "abstract": "Chronic myeloid leukemia (CML) is driven by the BCR-ABL fusion oncoprotein, a constitutively active tyrosine kinase whose inhibition by tyrosine kinase inhibitors (TKIs) transformed disease management. However, kinase-domain mutations, persistent leukemic stem cells (LSCs), and kinase-independent survival mechanisms still limit durable treatment-free remission. Increasing evidence indicates that BCR-ABL is regulated not only by kinase activity but also by post-translational modifications (PTMs) determining protein stability, turnover, interactions, and degradation. In this review, we examine how ubiquitination, SUMOylation, NEDDylation, phosphorylation, and acetylation-associated chaperone regulation control BCR-ABL proteostasis. Ubiquitin-dependent regulation involves opposing activities of E3 ligases and deubiquitinating enzymes, while TRIM28-mediated SUMOylation and RAPSYN-mediated NEDDylation stabilize BCR-ABL by limiting p62-dependent autophagic and c-CBL-mediated degradation, respectively. Crosstalk among these pathways suggests an integrated PTM network governs BCR-ABL fate rather than independent modifications. These mechanisms may impact persistent CML populations, though direct evidence linking specific PTMs to LSC maintenance remains limited. Therapeutically, manipulating PTM-dependent proteostasis via deubiquitinase inhibition, SUMO/NEDD8 modulation, chaperone disruption, and targeted protein degradation can complement conventional kinase inhibition. Notably, BCR-ABL-directed proteolysis-targeting chimeras (PROTACs) demonstrate the feasibility of eliminating the fusion protein rather than solely suppressing its catalytic activity. Ultimately, PTM-dependent proteostasis represents a critical regulatory dimension and therapeutic vulnerability in CML. Defining the spatial, temporal, and disease-specific PTM landscape of BCR-ABL is essential to determine if selective stability manipulation can overcome resistance and deepen therapeutic responses.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Biochemistry and Molecular Biophysics, University of California San Diego, La Jolla, CA 92093-0367, USA",
    "UCSD Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0367, USA"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Tara Shammas",
      "orcid": "0009-0002-0313-7128"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Daniel J. Donoghue",
      "orcid": "0000-0002-4546-2175"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/1ggyr7atga53v.bib",
  "cited_by": 0,
  "doi": "10.3390/ijms272210231",
  "fulltext_url": null,
  "id": "1ggyr7atga53v",
  "issns": [
    "1422-0067"
  ],
  "landing_url": "https://www.mdpi.com/1422-0067/27/22/10231",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-15",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/1ggyr7atga53v.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:24:18Z",
      "native_id": "10.3390/ijms272210231",
      "source": "crossref",
      "url": "https://www.mdpi.com/1422-0067/27/22/10231"
    }
  ],
  "subjects": [
    {
      "field": "biochemistry",
      "origin": "issn:1422-0067",
      "subfield": "general"
    }
  ],
  "title": "The Role of Ubiquitination and Ubiquitin-like Modifications in the Oncogenic Fusion Protein BCR-ABL",
  "title_text": "The Role of Ubiquitination and Ubiquitin-like Modifications in the Oncogenic Fusion Protein BCR-ABL",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:24:18Z",
  "url": "https://research.draconitic.com/paper/1ggyr7atga53v",
  "venue": "International Journal of Molecular Sciences",
  "versions": []
}